Market closed
IN8bio/$INAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IN8bio
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Ticker
$INAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
18
Website
IN8bio Metrics
BasicAdvanced
$13M
-
-$0.57
0.03
-
Price and volume
Market cap
$13M
Beta
0.03
52-week high
$0.29
52-week low
$0.13
Average daily volume
1M
Financial strength
Current ratio
4.08
Quick ratio
3.607
Long term debt to equity
23.366
Total debt to equity
34.742
Management effectiveness
Return on assets (TTM)
-67.70%
Return on equity (TTM)
-154.44%
Valuation
Price to book
0.8
Price to tangible book (TTM)
0.8
Price to free cash flow (TTM)
-0.35
Growth
Earnings per share change (TTM)
-43.43%
3-year earnings per share growth (CAGR)
-27.14%
IN8bio News
AllArticlesVideos
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
GlobeNewsWire·4 weeks ago
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
GlobeNewsWire·1 month ago
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for IN8bio stock?
IN8bio (INAB) has a market cap of $13M as of April 16, 2025.
What is the P/E ratio for IN8bio stock?
The price to earnings (P/E) ratio for IN8bio (INAB) stock is 0 as of April 16, 2025.
Does IN8bio stock pay dividends?
No, IN8bio (INAB) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next IN8bio dividend payment date?
IN8bio (INAB) stock does not pay dividends to its shareholders.
What is the beta indicator for IN8bio?
IN8bio (INAB) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.